|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 113.9 EUR | -2.57% |
|
-5.48% | +5.56% |
| 12/06 | Ipsen: share price soars, UBS confirms its recommendation | CF |
| 12/06 | IPSEN : UBS remains Buy after FDA approval | CF |
June 10 (Reuters) - The U.S. Food and Drug Administration has approved French drugmakers Ipsen and Genfit's drug to treat a chronic inflammatory liver disease, Ipsen said on Monday. (Reporting by Puyaan Singh in Bengaluru; Editing by Alan Barona)
| 1st Jan change | Capi. | |
|---|---|---|
| +5.56% | 1.01TCr | |
| +51.63% | 80TCr | |
| +41.51% | 63TCr | |
| -5.10% | 36TCr | |
| +19.90% | 33TCr | |
| +9.95% | 30TCr | |
| +17.66% | 24TCr | |
| +3.39% | 23TCr | |
| +10.75% | 21TCr | |
| +6.99% | 17TCr |
IPSEN 
